An interventional study of Electronic-Textile-based Electrocardiographic Monitoring in Cardiac Arrhythmia, sponsored by Myant Medical Corp.. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Myant Medical Corp. · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Arrhythmias, Cardiac with a site in Canada — 13 open to participants now, 15 under way, none of them phase 3. Arrhythmias, Cardiac · Canada.
Among the 73 studies in Arrhythmias, Cardiac with a site in Canada, this one is the 20th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2025, is one of 25 with no phase, reaches primary completion later than 8 of the 14 other live ones, and was the 72nd registered.
1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.
Browse Arrhythmias, Cardiac studies →13 of the 73 studies in Arrhythmias, Cardiac with a site in Canada are open now. Recruiting first, the newest first:
Cardurion Pharmaceuticals, Inc. · Sites in Canada, United States, France and 3 more countries
Ages 18–99
Novartis Pharmaceuticals · Sites in Canada, United States, China and 4 more countries
Ages 18+
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18–80 · Healthy volunteers
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 13 · Phase 4 3
First in 1983; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 100 across 518 interventional studies indexed under Arrhythmias, Cardiac.
Median enrollment 240 across the 49 interventional studies, 172 across the 24 observational. Of the 53 that completed or were terminated, 13 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 73 have an industry lead sponsor. The 10 most frequent:
Myant Medical Corp. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Myant Medical Corp. has 2 studies filed under Arrhythmias, Cardiac — fewer than ten, so there is no comparison to draw.
9 of the studies in Arrhythmias, Cardiac with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05258422McGill University Health Centre/Research Institute of the McGill University Health CentreStereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT) | 2026-12-31 |
| NCT06164808HelpWear Inc.Cardiac Arrhythmia Telemetry; Conventional vs HeartWatch | 2026-12-31 |
| NCT06174220Hamilton Health Sciences CorporationTargeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | 2027-02-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 73 studies in Arrhythmias, Cardiac with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research is a clinical evaluation of the Skiin chest band, a smart garment with embedded electronic textile (e-textile) electrodes, to record body surface electrocardiogram (ECG) signals. Developed by Myant Textile Computing Inc., the Skiin chest band (i.e. as part of the Skiin Underwear family of garments) is a component of the Myant Health Platform (MHP). The MHP also consists of: (a) a mobile phone application (Skiin Connected Life Application; SCLA), and (b) the Myant Virtual Clinic Portal (MVCP). In this study, participants will wear the Skiin chest band to collect their ECG for a period of 14 days. Participants will also be provided with a smartphone that is pre-loaded with the SCLA to record any symptoms (e.g. palpitations, shortness of breath, fatigue, light- headedness, fainting, etc.) they may experience over the 14 day ECG monitoring period. The data collected in this study will be used to develop new algorithms and patient monitoring tools to detect and predict cardiovascular health problems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this study, a total of 300 participants are expected to participate, specifically: The target population for this study are adults above 18 years of age with cardiovascular disease and/or risk factors, who have been prescribed a 14-day ambulatory ECG monitoring by their physician.
Device: Electronic-Textile-based Electrocardiographic Monitoring
Participants will be invited to wear the Skiin chest band for up to 14 days, as prescribed by their physician. Participants will wear the Skiin chest band in a similar capacity to a conventional Holter monitor.
Arrhythmia Detection
To evaluate the performance of Skiin chest band in collecting ambulatory body surface ECG, and in detecting the presence or absence of arrhythmias for up to 14 days
Time frame: Each participant undergoes up to 14 day ambulatory ECG monitoring from the time of wearing the Skiin chest band.
Algorithm Validation (Arrhythmia detection)
To validate an artificial intelligence/ machine learning (AI/ML) arrhythmia detection algorithm
Time frame: Each participant undergoes up to 14 day ambulatory ECG monitoring from the time of wearing the Skiin chest band.
Algorithm Validation (Atrial Fibrillation Burden)
To use the AI/ML arrhythmia detection algorithm to establish Atrial Fibrillation burden, defined as: the ratio of time spent in Atrial Fibrillation over total monitoring duration (i.e. up to 14 days)
Time frame: Each participant undergoes up to 14 day ambulatory ECG monitoring from the time of wearing the Skiin chest band.
Usability Rating
To evaluate the usability of the Skiin chest band for ambulatory ECG monitoring, as rated by study participants on the associated usability questionnaire. The questionnaire, entitled "Smart Textile ECG Monitoring (PACE-MYANT) - Usability Questionnaire". The questionnaire includes 16 questions that are answered on a 7-point Likert scale, in addition to other questions, where participants. The ratings in the the 7-point Likert scale (sections A) are "Strongly Disagree", "Disagree", Somewhat Disagree", "Neither agree nor disagree", "Somewhat Agree", "Agree", "Strongly Agree". Higher ratings and scores indicate better usability and overall experience. The ratings in the sections C are from 1 to 7: "Strongly favor other Holter", "Favor other Holter", "Somewhat Favor other Holter", "No preference", "Somewhat favor Skiin", "Favor Skiin", "Strongly favor Skiin". Higher ratings and scores indicate preference for Skiin vs. standard Holter monitoring with wires and adhesive patches.
Time frame: Each participant undergoes up to 14 day ambulatory ECG monitoring from the time of wearing the Skiin chest band.
Clinic Workflow Statistics
To document workflow statistics for Skiin ambulatory ECG monitoring in terms of (a) patient set-up s (i.e. the time it takes (in minutes) to set up a patient with the Skiin, and (b) report processing time (i.e. the time it takes for the ECG technician to scan/process the ambulatory ECG results?
Time frame: Before and after ambulatory ECG monitoring (up to 14 days) for each patient
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Sep 2027, 30 months after the start.
Of 71 industry-sponsored interventional studies with no phase under Arrhythmias, Cardiac, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 30 months is above that.
Counting every sponsor, half of 243 studies reached it within 24 months; a quarter within 12 and three quarters within 40.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Feb 2026 → Sep 2027 and completion Feb 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myant Medical Corp.